Protein News and Research

RSS
Astute Medical announces completion of $40.4M Series C financing

Astute Medical announces completion of $40.4M Series C financing

Clinical study shows positive effects of CAD106 vaccine against AD

Clinical study shows positive effects of CAD106 vaccine against AD

Paper spotlights unique developmental strategy undertaken by all mammals

Paper spotlights unique developmental strategy undertaken by all mammals

Cellana launches ReNew line of products at GOED conference

Cellana launches ReNew line of products at GOED conference

New research into cell-damaging effects of Huntington's disease

New research into cell-damaging effects of Huntington's disease

Study suggests link between fungi and ulcerative colitis

Study suggests link between fungi and ulcerative colitis

Plasma levels of tau appear to be a strong predictor for AD

Plasma levels of tau appear to be a strong predictor for AD

Debiopharm announces results from Debio 0932 Phase I study on cancer

Debiopharm announces results from Debio 0932 Phase I study on cancer

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Pioneering new test can quickly diagnose coeliac disease

Pioneering new test can quickly diagnose coeliac disease

Device to monitor gum disease

Device to monitor gum disease

New tool helps researchers to better understand Type 2 human diabetes

New tool helps researchers to better understand Type 2 human diabetes

AB Science announces data from development program of masitinib in GIST

AB Science announces data from development program of masitinib in GIST

InVitria receives new SBIR grant from NIAID

InVitria receives new SBIR grant from NIAID

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

FDA issues complete response letter to Merck’s ridaforolimus NDA

FDA issues complete response letter to Merck’s ridaforolimus NDA

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

New immune response data from Generex’s AE37 Phase II trial on breast cancer

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Three-drug regimen provides rapid, durable responses for multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.